INTRODUCTION AND OBJECTIVES:
Treating radiation changes to the bladder can be difficult for intractable symptoms. Our aim was to investigate whether surgical intervention for severe radiation cystitis was efficacious by objectively quantifying improvement in quality of life.
METHODS: We examined our IRB institutional database of 286 radiation cystitis patients from 2011 to 2017, and identified 45 patients who underwent definitive surgical management. Of these, 61% of patients underwent cystectomy during surgery. We identified quality of life measures that could be studied pre-operatively and post-operatively for comparison.
RESULTS: Patients who developed severe radiation cystitis requiring definitive surgical management typically presented 10 years after completing radiation therapy. The patient characteristics, including radiation type, reason for radiation, and perioperative information are demonstrated in Table 1 . Regarding urinary diversion, 89% of patients had ileal conduits, 9% of patients had continent urinary reservoirs, and one patient only had cystectomy with bilateral nephrostomy tubes for diversion. Intractable symptoms requiring definitive surgical management included incontinence (38%), refractory hematuria (22%), urinary tract strictures (20%), fistula (11%), pelvic pain (7%), and bladder cancer (2%). We continued to follow patients with a mean follow up time of 14.6 months. We found that these patients after surgery required fewer post-operative procedures, hospitalizations, and transfusions as seen in Figure 1 .
CONCLUSIONS: The toxicity of radiation can be debilitating years after completing treatment. Our institutional findings suggest definitive surgical management for intractable symptoms can significantly improve quality of life measures. is a debilitating side effect from radiation therapy that develops in approximately 10% of pelvic cancer survivors who received radiation therapy. Histologically, radiation therapy causes bladder inflammation, fibrosis and vascular damage. We previously reported elevated angiogenic growth factors in the urine of RC patients, hereby indicating ongoing vascular damage in these patients. Here, we investigated the effect of radiation therapy on fibrotic factors (e.g. MMP's and TIMP's) in the urine. We hypothesize that radiation-induced fibrosis in the bladder is detectable in the urine through altered protein levels of fibrotic factors. Together with our angiogenic growth factor panel, these fibrotic factors can serve as an individualized diagnostic tool for early diagnosis of RC prior to the onset of symptoms.
METHODS: Urine samples were collected from prostate cancer survivors with a history of external beam therapy. Urine of healthy men and of prostate cancer survivors that did not receive radiation therapy were used as normal control samples. Levels of fibrotic factors in the urine were measured using Luminex Multiplex assay (Millipore).
RESULTS: 76 prostate cancer survivors with a history of radiation therapy provided a urine sample and filled out a survey on urinary symptoms. Urine samples were tested for a panel of fibrotic factors. MMP-9, MMP-10, TIMP-1, TIMP-2, PAI-1 and Cathepsin-D were detectable in human urine samples and were elevated when compared to RC status, frequency, IC/BPS symptom score, and/or the presence of hematuria.
CONCLUSIONS: RC can develop in pelvic cancer survivors and is characterized in part by bladder fibrosis and vascular damage/ hemorrhaging. RC is diagnosed by ruling out other conditions and through invasive procedures (e.g. cystoscopy). Our studies indicate radiation-induced changes in fibrotic factors that are detectable in the urine. These factors could be useful biomarkers in the era of personalized medicine for early non-invasive detection of radiation cystitis.
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